Healthcare Industry News: linear accelerator
News Release - March 12, 2009
Orbital Therapy Receives 510(k) Clearance for the Clearvue(TM) Prone Position Breast Radiotherapy Treatment TableBedford, MA, Mar 12, 2009 – (HSMN NewsFeed) - Orbital Therapy announces 510(k) clearance to market the ClearVue(TM) Prone Position Breast Radiotherapy Treatment Table in the United States.
ClearVue(TM) is a carbon fiber add-on treatment table used to simulate and treat breast cancer patients in the prone position. ClearVue(TM) can be used with existing CT simulators and linear accelerators to plan and deliver radiation treatments.
ClearVue(TM) is unique in its ability to provide full visual access to the anatomy for precise set-up and treatment delivery," explained Orbital Therapy's chief technology officer Alan Sliski. "The open design enables the clinician to plan a treatment from more than two conventional angles and to utilize more complex techniques that are already in use as cancer therapies with other anatomies."
The use of prone position to treat breast cancer is rapidly gaining popularity. Prone position increases the distance between the target and surrounding critical organs and minimizes or eliminates target motion caused by breathing. This results in less radiation dose to organs such as the lung and heart and more precise dose to the intended target.
Orbital Therapy’s carbon fiber ClearVue(TM) prone position table was designed to address current and future requirements to deliver this promising therapy technique. As many studies begin to point to accelerated and partial breast radiation treatments, precise patient positioning and open access to the breast are becoming of greater importance.
About Orbital Therapy, LLC
Orbital Therapy was founded in 2006 to develop products for the treatment of breast cancer. Our innovative approach to the treatment of this particular disease will offer numerous benefits over currently used techniques and provide many benefits to the patient, as well as the care provider.
Source: Orbital Therapy
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.